Author

J. Casado

Listed by name: these papers carry no ORCID for this author, so different people with the same name may be mixed together.

Biology Disciplines

Click to filter author papers

Cancer Biology· 3

Signature Assays, Organisms & Methods

Click to filter · or open tag

Organism:human· 3 Research Focus:cancer & tumor microenvironment· 1 Research Focus:cell type annotation· 1 Research Focus:cell-cell communication· 1 Approach:deep learning· 1 Research Focus:differential expression· 1 Approach:experimental assay· 1 Research Focus:gene regulatory network inference· 1

Frequent Co-Authors

A. Farkkila· 2 shared L. Kauppi· 2 shared M. Tumiati· 2 shared S. Hautaniemi· 2 shared A. Chernenko· 1 shared A. Junquera Mencia· 1 shared A. Laury· 1 shared A. Szabo· 1 shared

Activity by Year

2019-2023 · peak 1/yr

Co-Author Collaboration Network

10 top collaborators · 24 mutual co-author links

Click any collaborator node to inspect or filter shared papers

Focal author (center)Selected co-authorORCID co-authorUnlinked name

Curved chords = mutual co-authorship

2 shared papersCancer Biology

A. Farkkila

Mutual co-authors in cluster

Author profile →

3 papers

Recent·Most cited

Single-cell spatial atlas of tertiary lymphoid structures in ovarian cancer

J. Sarkkinen, A. Junquera Mencia, E. Anttila, A. Szabo, F. Perez, I.-M. Launonen, A. Laury, J. Casado, E. Kekalainen, A. Farkkila

This study creates a single-cell spatial atlas of tertiary lymphoid structures (TLSs) in ovarian cancer, revealing distinct TME composition, gene expression profiles, and cell-cell interactions associated with TLSs.

bioRxiv · May 16, 2023 · PreprintCancer Biology

Optimized detection of allelic imbalances specific for homologous recombination deficiency improves the prediction of clinical outcomes in cancer

F. Perez-Villatoro, J. Oikkonen, J. Casado, A. Chernenko, D. C. Gulhan, M. Tumiati, Y. Li, K. Lavikka, S. Hietanen, J. Hynninen, U.-M. Haltia, J. S. Tyrmi, H. Laivuori, P. Konstantinopoulos, S. Hautaniemi, , A. Farkkila

The paper develops a tumor-specific method to detect allelic imbalances for HRD prediction, showing improved clinical outcome prediction in ovarian and breast cancers.

bioRxiv · Aug 19, 2021Cancer Biology

Epigenetic inhibitors sensitize DLBCL cells to rituximab and doxorubicin

C. Facciotto, J. Casado, L. Turunen, S.-K. Leivonen, M. Tumiati, V. Rantanen, L. Kauppi, R. Lehtonen, S. Leppä, K. Wennerberg, S. Hautaniemi

This study identifies epigenetic inhibitors that enhance the effectiveness of immunochemotherapy in DLBCL by disrupting DNA repair and cell cycle pathways.

bioRxiv · Feb 6, 2019 · PreprintCancer Biology